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Articles

The incidence, aetiology, and adverse clinical consequences
of less severe diarrhoeal episodes among infants and children
residing in low-income and middle-income countries:
a 12-month case-control study as a follow-on to the Global
Enteric Multicenter Study (GEMS)
Karen L Kotloff, Dilruba Nasrin, William C Blackwelder, Yukun Wu*, Tamer Farag†, Sandra Panchalingham, Samba O Sow, Dipika Sur‡,
Anita K M Zaidi§, Abu S G Faruque, Debasish Saha¶, Pedro L Alonso, Boubou Tamboura, Doh Sanogo, Uma Onwuchekwa, Byomkesh Manna,
Thandavarayan Ramamurthy, Suman Kanungo, Shahnawaz Ahmed, Shahida Qureshi, Farheen Quadri, Anowar Hossain, Sumon K Das,
Martin Antonio, M Jahangir Hossain, Inacio Mandomando, Sozinho Acácio, Kousick Biswas, Sharon M Tennant, Jaco J Verweij||,
Halvor Sommerfelt, James P Nataro**, Roy M Robins-Browne, Myron M Levine

Summary

Background Diarrheal diseases remain a leading cause of illness and death among children younger than 5 years in
low-income and middle-income countries. The Global Enteric Multicenter Study (GEMS) has described the incidence,
aetiology, and sequelae of medically attended moderate-to-severe diarrhoea (MSD) among children aged 0–59 months
residing in censused populations in sub-Saharan Africa and south Asia, where most child deaths occur. To further
characterise this disease burden and guide interventions, we extended this study to include children with episodes of
less-severe diarrhoea (LSD) seeking care at health centres serving six GEMS sites.
Methods We report a 1-year, multisite, age-stratified, matched case-control study following on to the GEMS study.
Six sites (Bamako, Mali; Manhiça, Mozambique; Basse, The Gambia; Mirzapur, Bangladesh; Kolkata, India; and Bin
Qasim Town, Karachi, Pakistan) participated in this study. Children aged 0–59 months at each site who sought care at a
sentinel hospital or health centre during a 12-month period were screened for diarrhoea. New (onset after ≥7 diarrhoeafree days) and acute (onset within the previous 7 days) episodes of diarrhoea in children who had sunken eyes, whose
skin lost turgor, who received intravenous hydration, who had dysentery, or who were hospitalised were eligible for
inclusion as MSD. The remaining new and acute diarrhoea episodes among children who sought care at the same
health centres were considered LSD. We aimed to enrol the first eight or nine eligible children with MSD and LSD at
each site during each fortnight in three age strata: infants (aged 0–11 months), toddlers (aged 12–23 months), and young
children (aged 24–59 months). For each included case of MSD or LSD, we enrolled one to three community control
children without diarrhoea during the previous 7 days. From patients and controls we collected clinical and
epidemiological data, anthropometric measurements, and faecal samples to identify enteropathogens at enrolment, and
we performed a follow-up home visit about 60 days later to ascertain vital status, clinical outcome, and interval growth.
Primary outcomes were to characterise, for MSD and LSD, the pathogen-specific attributable risk and population-based
incidence values, and to assess the frequency of adverse clinical consequences associated with these two diarrhoeal
syndromes.
Findings From Oct 31, 2011, to Nov 14, 2012, we recruited 2368 children with MSD, 3174 with LSD, and one to three
randomly selected community control children without diarrhoea matched to cases with MSD (n=3597) or LSD
(n=4236). Weighted adjusted population attributable fractions showed that most attributable cases of MSD and LSD
were due to rotavirus, Cryptosporidium spp, enterotoxigenic Escherichia coli encoding heat-stable toxin (with or without
genes encoding heat-labile enterotoxin), and Shigella spp. The attributable incidence per 100 child-years for LSD
versus MSD, by age stratum, for rotavirus was 22·3 versus 5·5 (0–11 months), 9·8 versus 2·9 (12–23 months), and
0·5 versus 0·2 (24–59 months); for Cryptosporidium spp was 3·6 versus 2·3 (0–11 months), 4·3 versus 0·6
(12–23 months), and 0·3 versus 0·1 (24–59 months); for enterotoxigenic E coli encoding heat-stable toxin was
4·2 versus 0·1 (0–11 months), 5·2 versus 0·0 (12–23 months), and 1·1 versus 0·2 (24–59 months); and for Shigella
spp was 1·0 versus 1·3 (0–11 months), 3·1 versus 2·4 (12–23 months), and 0·8 versus 0·7 (24–59 months). Participants
with both MSD and LSD had significantly more linear growth faltering than controls at follow-up.
Interpretation Inclusion of participants with LSD markedly expands the population of children who experience
adverse clinical and nutritional outcomes from acute diarrhoeal diseases. Since MSD and LSD have similar aetiologies,
interventions targeting rotavirus, Shigella spp, enterotoxigenic E coli producing heat-stable toxin, and Cryptosporidium
spp might substantially reduce the diarrhoeal disease burden and its associated nutritional faltering.
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Introduction
The Global Enteric Multicenter Study (GEMS) was a
prospective, age-stratified, matched case-control study of
the burden, aetiology, and adverse clinical outcomes of
diarrhoeal diseases among children aged 0–59 months
seeking care at health-care facilities during a 36-month
period at seven sites in sub-Saharan Africa and south
Asia.1,2 GEMS aimed to identify the most clinically severe,
medically attended diarrhoeal episodes to guide and
prioritise efforts to prevent the most life-threatening and
disabling illnesses. It is also important to characterise the
less-severe diarrhoea (LSD) episodes for which care is
sought at health-care facilities, recognising that even
though there might be fewer adverse health consequences
from LSD, its overall burden could be greater than that of
moderate-to-severe diarrhoea (MSD) because it is more
common. Whether there are meaningful differences in
the distribution of aetiologies of LSD compared with MSD
must also be understood to optimise diarrhoeal disease
prevention and treatment. Herein we describe a 1-year
follow-on study designated GEMS-1A in which six GEMS
sites did simultaneous case-control studies of both MSD
and LSD to measure the pathogen-specific attributable
risk and population-based incidence for LSD in addition
to MSD—so the total burden of medically attended
diarrhoeal disease in low-income and middle-income

countries could be described—and to assess the frequency
of adverse clinical consequences of these two syndromes.

Methods

Study design and participants
GEMS-1A is a 1-year, multisite, age-stratified, matched
case-control study following on to the GEMS study.1
Six GEMS sites with moderate-to-high mortality of
children younger than 5 years participated in GEMS-1A,
three in Africa (Bamako, Mali; Manhiça, Mozambique;
and Basse, The Gambia) and three in Asia (Mirzapur,
Bangladesh; Kolkata, India; and Bin Qasim Town,
Karachi, Pakistan).1 The estimated number of LSD cases
at the GEMS site in Kenya was projected to be insufficient
for participation in GEMS-1A. Participants at each site
belonged to a censused population serially updated for
births, deaths, and migrations using a demographic
surveillance system (DSS). For participant enrolment,
site investigators selected sentinel hospitals or health
centres where children included in the DSS sought care
for diarrhoeal illnesses.1
All children aged 0–59 months belonging to the DSS
population at each site who sought care at a sentinel
hospital or health centre during a 12-month period were
screened for diarrhoea (three or more loose stools during
the previous 24 h).3 Episodes eligible for inclusion as

Research in context
Evidence before this study
Before this study, we did a systematic review of epidemiological
studies seeking to determine the causes and adverse sequelae
of paediatric diarrhoea in low-income countries. We searched
PubMed for new studies and review articles published between
Jan 1, 1980, and Aug 31, 2018, using the search string
(“diarrhea*”[All Fields] OR “gastroenteritis”[All Fields]) AND
(“pediatric”[All Fields] OR “child*”[All Fields]) AND
(“*etiology”[All Fields] OR “growth faltering”[All Fields] OR
“stunting”[All Fields]) AND (“developing countr*”[All Fields] OR
“low-income”[All Fields]). We included older reports, and
articles identified in reference lists when appropriate. We
identified methodologic limitations that led to knowledge gaps
about the epidemiology of diarrhoeal disease among children
living in developing countries. We then designed and did the
Global Enterics Multicenter Study (GEMS) to elucidate the
incidence, aetiology, and adverse clinical consequences of
medically attended moderate-to-severe diarrhoea (MSD)
among children younger than 5 years living in developing
countries. However, GEMS left unanswered questions about
whether the findings of GEMS were generalisable to episodes of
less-severe diarrhoea (LSD), which represent the majority of
paediatric diarrhoea in patients presenting to health-care

centres. Therefore, we updated our literature search and
designed this study to simultaneously examine MSD and LSD.
Added value of this study
Using a rigorous study design and microbiological methods
capable of detecting a broad array of pathogens across a diverse
set of study sites with medium and high under-5 mortality,
we showed that inclusion of LSD defines a far greater burden of
disease without substantially altering the four most important
aetiological pathogens involved—ie, rotavirus, Cryptosporidium
spp, enterotoxigenic Escherichia coli producing heat-stable
toxin, and Shigella spp. While children with LSD are less acutely
ill than those with MSD, particularly with regard to dehydration,
they have similar susceptibility to linear growth faltering
following their diarrhoeal episode relative to their matched
healthy controls.
Implications of all the available evidence
These findings expand the population of children experiencing
adverse clinical and nutritional consequences of acute diarrhoeal
illness in low-resource settings. Since MSD and LSD have similar
aetiologies, mitigation of disease associated with a restricted
number of aetiological agents can substantially reduce the
diarrhoeal disease burden and its associated nutritional faltering.
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MSD were new (onset after ≥7 diarrhoea-free days) and
acute (onset within the previous 7 days) episodes in
children who satisfied at least one of these criteria: had
sunken eyes (confirmed by parent or caretaker as more
than normal); decreased skin turgor (abdominal skin
pinch with slow or very slow [>2 s] recoil); intravenous
hydration administered or prescribed; had dysentery
(reported or visible blood in loose stools); or were
hospitalised.1,2 Eligibility was assessed by the child’s
clinician in conjunction with the study staff. The
remaining new and acute diarrhoea episodes among
children aged 0–59 months of age belonging to the DSS
who sought care at the same health centres during the
12-month study period and did not meet the case
definition of MSD were considered LSD. We aimed to
enrol the first eight or nine eligible children with MSD
and LSD at each site during each fortnight in three age
strata: infants (aged 0–11 months), toddlers (aged
12–23 months), and young children (aged 24–59 months).1
For each included case of MSD or LSD, we enrolled
one-to-three community control children without diar
rhoea during the previous 7 days.1 Using a computer
algorithm, at least four children were randomly selected
from the site’s DSS database among those who matched
each individual enrolled patient by age, gender, and
residence (same or nearby village or neighbourhood as
the patient) according to predefined criteria.1 A field
worker visited the homes of each selected child and
sequentially enrolled, within 14 days of the diarrhoeal
episode, the requisite number of children who met
eligibility criteria.1
The clinical protocol was approved by ethics committees
at the University of Maryland (Baltimore, MD, USA) and
those overseeing investigators at the field sites. Written
informed consent was obtained from the parent or
primary caretaker of each participant.

Procedures
The primary outcomes of the GEMS-1A study were to
characterise, for LSD in addition to MSD, the overall
and pathogen-specific population-based attributable
incidence and the pathogen-specific attributable fraction,
and to assess the frequency of nutritional faltering and
other adverse clinical consequences among children
with these two diarrhoeal syndromes relative to the
control population. The outcomes were assessed by site
and age stratum, and across all sites for incidence and
nutritional outcomes. Since dysentery was an exclusion
criterion for LSD, we included a category non-dysentery
MSD to compare syndromes of watery diarrhoea for
analyses of attributable fraction and pathogen-specific
incidence.
Other primary outcomes—eg, the mortality and
frequency of persistent diarrhoea in children with LSD
and MSD—will be published elsewhere.
GEMS-1A generally used the same clinical,1 epide
miological,1 microbiological,4 data management,5 and
www.thelancet.com/lancetgh Vol 7 May 2019

analytical6 methods described for GEMS, unless
otherwise specified. At the time of these studies, no
site had introduced rotavirus vaccine into its Expanded
Programme on Immunization for infants.
To estimate population-based diarrhoeal disease, we did
brief surveys on health-care utilisation and attitudes
concurrent with the GEMS-1A case-control study using
random samples of children.7 For children who had
experienced diarrhoea in the previous 7 days, the primary
caretaker was queried about clinical symptoms and
health-care use for the episode. For each site and age
stratum, we calculated the proportion of children who
were taken to a sentinel hospital or health centre within
7 days of onset of diarrhoea and the pathogen-specific
incidence per 100 child-years in the DSS population.6
At enrolment, parents or primary caretakers of all
participants underwent standardised interviews to solicit
demographic, epidemiological, and clinical information.
GEMS staff measured each child’s length or height.1
Medical management by clinicians at the sentinel hospital
or health centre and clinical condition upon discharge
were documented. A single follow-up home visit was
done about 60 days after enrolment (range 50–90 days) to
assess the child’s vital status and repeat anthropometric
measurements.
At enrolment, each participant provided fresh stool
that was placed in cold storage and transport media
according to the protocol.1 If antibiotics were to be
administered to participants with diarrhoea before stool
was produced, we obtained two rectal swabs for bacterial
culture pending passage of the whole stool for the
remaining assays.1
Putative enteropathogens (Salmonella, Shigella, Campy
lobacter, Aeromonas, and Vibrio spp, diarrhoeagenic
Escherichia coli [enterotoxigenic, enteropathogenic, entero
aggregative, and Shiga toxin-producing], rotavirus, adeno
virus serotypes 40 and 41, norovirus genotypes I and II,
sapovirus, astrovirus, Giardia intestinalis, Entamoeba
histolytica, and Cryptosporidium spp) were identified in
cases and controls as previously described4 with some
exceptions. E coli strains were first tested using a
multiplex PCR as described for GEMS.4 An additional
duplex PCR (appendix) was incorporated with primers to
detect E coli encoding porcine heat-stable toxin and with
alternative primers that detect eae but that generate a
smaller eae amplicon than the first multiplex PCR. E coli
that were eae+ and bfp– were subsequently tested for bfp
in a monoplex PCR. E coli that were eae+ and bfp–
were subsequently tested using a multiplex PCR with
primers for stx1, stx2, eae, efa-1 (enterohaemorrhagic
E coli), and sen (enteropathogenic E coli). We also detected
a Helicobacter pylori antigen by the Amplified IDEIA Hp
StAR immunoassay (Oxoid, Thermofisher, Cambridge,
UK), intestinal geohelminths (Ascaris lumbricoides,
Strongyloides stercoralis, and human hookworms [Necator
americanus and Ancylostoma duodenale]) using multiplex
real-time PCR,8,9 Bacteroides fragilis enterotoxin gene (bftP)

Correspondence to:
Dr Karen L Kotloff, Center for
Vaccine Development, University
of Maryland School of Medicine,
Baltimore, 21201 MD, USA
kkotloff@som.umaryland.edu

See Online for appendix
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by gel-based PCR on DNA extracted from stools,10 and
Clostridium difficile using the C diff Quik Chek Complete
dual antigen immunoassay (TechLab, Blacksburg VA,
USA) by finding positivity to C difficile glutamatedehydrogenase antigen and identifying the presence of
toxins A or B.

15 896 patients from the DSS
with diarrhoea presented
at the hospital and
assessed for eligibility

970 ineligible*

Statistical analysis
14 926 eligible
3717 eligible as MSD case
11 209 eligible as LSD case

7833 control children selected†

9384 excluded from
enrolment
1349 with MSD
8035 with LSD

13 375 enrolled and included in
aetiology analysis
5542 patients
2368 with MSD
3174 with LSD
7833 controls
3597 controls (MSD)
4236 controls (LSD)

659 dropped out
333 patients
133 with MSD
200 with LSD
326 controls
164 controls (MSD)
162 controls (LSD)
45 died
23 with MSD
12 with LSD
3 controls (MSD)
7 controls (LSD)

Figure 1: Study profile
LSD=less-severe diarrhoea.
MSD= moderate-to-severe
diarrhoea. *Children were
ineligible if their diarrheal
episode had not started in
the past 7 days after
7 diarrhea-free days, or if they
were currently enrolled in the
study and undergoing
follow-up. †1–3 controls
matched for age, gender, time
of case presentation, and
location of residence were
selected randomly from the
census database and given a
stool collection kit; the first to
produce a stool was enrolled;
therefore, no controls were
excluded. ‡Cases and controls
were excluded from the
nutritional analysis if they met
criteria for an implausible value
for height for age at
enrollment or change in height
over the follow-up period.
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12 671 followed up
5174 patients
2212 with MSD
2962 with LSD
7497 controls
3430 controls (MSD)
4067 controls (LSD)

1016 excluded from nutrition
analysis‡
280 patients
125 with MSD
155 with LSD
736 controls
354 controls (MSD)
382 controls (LSD)

11 655 included in nutrition
analysis
4894 patients
2087 with MSD
2807 with LSD
6761 controls
3076 controls (MSD)
3685 controls (LSD)

The analytic methods used in GEMS-1A followed those
used in GEMS,11 with the additions described in this
section. We used Wald χ² tests to compare proportions
of children with MSD or LSD and their matched con
trols with different demographic features. In separate
analyses for MSD, non-dysentery MSD, and LSD,
associations with potential pathogens were assessed
with conditional logistic regression12 with a penalised
likelihood approach.13 In brief, a weighted population
attributable fraction14 for each pathogen significantly
associated with MSD or LSD was derived for each site
and age stratum from a multiple conditional logistic
regression model that adjusted for the presence of
other pathogens and interactions between pathogens.
Pathogens were included in the multiple conditional
logistic regression model if they were significant (p<0·1)
in a bivariate analysis and remained after a process of
backward elimination which used a prespecified p-value
cutoff of 0·05. The pathogen-specific attributable
fractions of non-dysentery MSD and LSD were compared
by calculating a Z score for their difference, with the
standard deviation of each attributable fraction estimated
by jackknife.15
Once the attributable fraction for each pathogen was
determined for each site and age stratum, we used the
proportion of children with MSD or LSD taken to one of
the site’s sentinel hospitals or health centres—obtained
from the data from the health-care utilisation and
attitudes surveys—to calculate the pathogen-specific
attributable incidence per 100 child-years in the DSS
population.6 This method assumes that the distributions
of aetiologies of MSD and LSD for children who sought
care at the sentinel hospital or health centre were similar
to the distributions for children who did not seek care.
To assess this assumption, we used the data from the
health-care utilisation and attitudes surveys to quali
tatively compare the severity of illness as determined by
caretakers’ reports of the clinical features of children
with MSD and LSD who did and did not seek care at a
sentinel hospital or health centre.
For LSD, MSD, and non-dysentery MSD, overall
pathogen-specific attributable incidence within each
age group were calculated as the sum over sites of
attributable cases (attributable fraction multiplied by
total cases at sentinel hospitals or health centres and
divided by the proportion of children with MSD or LSD
taken to one of the site’s sentinel hospitals or health
centres), divided by the sum over sites of median DSS
population. Standard errors of attributable incidence
www.thelancet.com/lancetgh Vol 7 May 2019
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at enrolment for patients and controls were compared
using weighted paired t tests; when a patient had multiple
controls, the average enrolment HAZ was used. The same
weights used for the diarrhoeal aetiology analysis were

values were approximated using Taylor series to first
derivative terms.
We derived length-for-age or height-for-age Z scores
(HAZs) using WHO standards.11,16 Weighted HAZ means
The Gambia
100

India
All MSD (n=124)
Non-dysentery MSD (n=94)
LSD (n=220)

90

All MSD (n=206)
Non-dysentery MSD (n=184)
LSD (n=213)

Atrtributable fraction (%)

80
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p=1·04

40
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p=0·00024
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10
0

RV

Crypto

ST ET E coli

RV

Crypto
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40/41
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All MSD (n=233)
Non-dysentery MSD (n=214)
LSD (n=236)

90
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All MSD (n=122)
Non-dysentery MSD (n=26)
LSD (n=183)

p=0·0010

Atrtributable fraction (%)

80
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p=1·13

20
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ST ET E coli

tEP E coli

AdV
non-40/41
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ST ET E coli

Shigella spp

Mozambique
100

Aeromonas
spp

AdV 40/41

NV GII

Pakistan
All MSD (n=65)
Non-dysentery MSD (n=62)
LSD (n=236)

90

AdV
non-40/41

All MSD (n=155)
Non-dysentery MSD (n=125)
LSD (n=227)

Atrtributable fraction (%)

80
70

p=0·0022

60
p=0·0052

50
p=0·045

40

p=0·021

30

p=0·81

20

p=0·81

10
0
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Crypto

RV
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ST ET E coli

Shigella spp
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Figure 2: Adjusted attributable fraction of pathogens significantly associated with LSD, non-dysentery MSD, and MSD, by site in the 0–11 months’ age group
Adjusted attributable fractions are expressed as weighted percent of total diarrhoeal episodes. Bars are 95% CIs. Differences in pathogen frequency according to the severity of watery diarrhoea were
evaluated by comparing non-dysentery MSD versus LSD using Z scores of the differences between non-dysentery MSD versus LSD. AdV=adenovirus. C jejuni=Campylobacter jejuni. CDT=Clostridium
difficile toxin. Crypto=Cryptosporidium spp. E coli=Escherichia coli. ET=enterotoxigenic. H pylori=Helicobacter pylori. LSD=less-severe diarrhoea. MSD=moderate-to-severe diarrhoea. NV GII=norovirus GII.
RV=rotavirus. ST=heat-stable-toxin producing. SV=sapovirus. tEP=typical enteropathogenic.
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to follow-up in patients and controls using weighted
linear regression models for all possible matched pairs,
adjusting for enrolment HAZ and duration of follow-up
and using jack-knife estimates of standard error.15

used for the weighted paired t tests.6 These weights were
also used in weighted linear regression analyses comparing
baseline HAZ scores in patients with MSD and patients
with LSD. We compared changes in HAZ from enrolment
The Gambia
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90

All MSD (n=165)
Non-dysentery MSD (n=144)
LSD (n=180)

Atrtributable fraction (%)

80
70
60
50
p=0·024

40
30
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Figure 3: Adjusted attributable fraction of pathogens significantly associated with LSD, non-dysentery MSD, and MSD, by site in the 12–23 months’ age group
Adjusted attributable fractions are expressed as weighted percent of total diarrhoeal episodes. Bars are 95% CIs. Differences in pathogen frequency according to the severity of watery diarrhoea were
evaluated by comparing non-dysentery MSD versus LSD using Z scores of the differences between non-dysentery MSD versus LSD. AdV=adenovirus. AstroV=astrovirus. CDT=Clostridium difficile toxin.
Crypto=Cryptosporidium spp. EA=enteroaggregative. E coli=Escherichia coli. E histolytica=Entamoeba histolytica. ET=enterotoxigenic. H pylori=Helicobacter pylori. LSD=less-severe diarrhoea.
MSD=moderate-to-severe diarrhoea. NV GII=norovirus GII. RV=rotavirus. ST=heat-stable-toxin producing. SV=sapovirus. V cholerae=Vibrio cholerae.
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Role of the funding source

Results with two-sided p values less than 0·05 were con
sidered significant. We did not apply any adjustment for
multiple comparisons. Statistical analyses were performed
in SAS version 9, SPSS version 24, and R version 3.3.2.

The funder of the study played no role in study design,
data collection, data analysis, data interpretation, or
writing of the report. The corresponding author had
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Figure 4: Adjusted attributable fraction of pathogens significantly associated with LSD, non-dysentery MSD, and MSD, by site in the 24–59 months’ age group
Adjusted attributable fractions are expressed as weighted percent of total diarrhoeal episodes. Bars are 95% CIs. Differences in pathogen frequency according to the severity of watery diarrhoea
were evaluated by comparing non-dysentery MSD versus LSD using Z scores of the differences between non-dysentery MSD versus LSD. B fragilis=Bacteroides fragilis. Crypto=Cryptosporidium spp.
E coli=Escherichia coli. E histolytica=Entamoeba histolytica. ET=enterotoxigenic. H pylori=Helicobacter pylori. LSD=less-severe diarrhoea. MSD=moderate-to-severe diarrhoea. NV GII=norovirus GII.
RV=rotavirus. ST=heat-stable-toxin producing. SV=sapovirus. V cholerae=Vibrio cholerae.
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The Gambia

Mali

Mozambique

India

Bangladesh

Pakistan

Total

LSD

67·9
(17·1–118·6)

98·3
(0·0–242·3)

65·6
(0·0–175·9)

82·6
(45·1–120·2)

118·4
(0·0–290·6)

161·4
(82·1–240·7)

105·0
(53·4–156·6)

Total MSD

15·2
(3·2–27·1)

35·7
(0·0–82·2)

5·2
(0·0–13·6)

51·7
(24·8–78·5)

9·7
(1·2–18·3)

43·1
(10·2–76·0)

27·7
(13·2–42·3)

Non–dysenteric MSD

12·2
(2·0–22·4)

29·3
(0·0–67·4)

4·3
(0·0–11·3)

50·7
(22·6–78·7)

1·7
(0·2–3·3)

32·2
(7·6–56·7)

21·7
(10·0–33·5)

LSD + MSD

83·0
(30·9–135·2)

134·0
(0·0–285·3)

70·8
(0·0–181·5)

134·3
(88·2–180·5)

128·1
(0·0–300·5)

204·4
(118·6–290·3)

132·7
(79·1–186·3)

LSD

48·8
(14·9–82·7)

57·6
(0·0–143·2)

53·2
(0·0–109·5)

89·6
(27·4–151·8)

23·3
(2·3–44·4)

189·4
(71·7–307·1)

72·2
(42·8–101·5)

Total MSD

20·5
(5·3–35·7)

33·6
(0·0–72·3)

6·7
(0·0–16·4)

51·5
(10·4–92·6)

11·5
(0·0–27·1)

21·0
(5·7–36·2)

23·2
(11·9–34·4)

Non–dysenteric MSD

11·5
(2·7–20·4)

25·2
(0·0–54·6)

6·1
(0·0–23·0)

52·8
(5·8–99·7)

1·8
(0·0–4·1)

14·7
(3·6–25·7)

16·4
(7·6–25·1)

LSD + MSD

69·3
(32·1–106·4)

91·2
(0·0–185·2)

59·9
(2·8–117·1)

141·1
(66·5–215·7)

34·8
(8·6–61·0)

210·4
(91·7–329·0)

95·3
(63·9–126·8)

LSD

8·2
(1·6–14·7)

17·6
(0·0–38·6)

9·8
(0·0–24·7)

21·0
(9·0–33·0)

7·8
(0·0–23·1)

32·9
(10·2–55·5)

16·3
(9·0–23·6)

Total MSD

3·1
(0·2–5·9)

5·7
(0·3–11·1)

1·0
(0·0–2·7)

30·5
(0·0–73·2)

3·8
(0·0–8·7)

2·5
(0·7–4·4)

5·9
(1·8–9·9)

Non–dysenteric MSD

1·7
(0·0–3·5)

5·5
(0·7–10·3)

0·5
(0·0–1·4)

20·2
(0·0–48·5)

0·6
(0·0–1·3)

1·4
(0·4–2·5)

3·8
(1·1–6·5)

LSD + MSD

11·2
(4·1–18·4)

23·3
(1·6–45·0)

10·8
(0·0–25·8)

51·5
(7·1–95.8)

11·6
(0·0–27·7)

35·4
(12·7–58·1)

22·2
(13·8–30·6)

0–11 months

12–23 months

24–59 months

Data are incidence per 100 child-years (95% CI).

Table 1: Incidence of moderate–to–severe diarrhoea (MSD) and less–severe diarrhoea (LSD) per 100–child–years of observation by site and age stratum

full access to all the data in the study and had final
responsibility for the decision to submit for publication.

Results
During a 12-month period between Oct 31, 2011, and
Nov 14, 2012, children aged 0–59 months of age included
in the DSS at six study sites (Bamako, Mali; Manhiça,
Mozambique; Basse, The Gambia; Mirzapur, Bangladesh;
Kolkata, India; and Bin Qasim Town, Karachi, Pakistan)
collectively made 192 086 visits to the study sentinel
hospitals or health centres, of which 15 896 (8·3%) were
by children experiencing diarrhoea; 11 209 (75·1%) of the
14 926 children with acute, new onset diarrhea had LSD
and 3717 (24·9%) had MSD. 2368 (63·7%) of 3717 children
with MSD and 3174 (28·3%) of 11 209 with LSD were
enrolled and analysable along with 3597 controls matched
to patients with MSD and 4236 controls matched to
patients with LSD (figure 1). 23 (1·0%) of 2368 children
with MSD, 12 (0·4%) of 3174 children with LSD, three
(<0·1%) of 3597 MSD controls, and seven (<0·1%) of
4236 LSD controls died after enrolment. Among living
children, a 60-day follow-up household visit was com
pleted for 2212 (94·3%) of 2345 children with MSD
and 2962 (93·7%) of 3162 children with LSD, and for
3430 (95·4%) of 3594 MSD controls and 4067 (96·2%) of
4229 LSD controls. When we compared the demographic
e575

features of children with LSD (appendix) and MSD
(appendix) to their matched controls, no trends were
apparent. The proportion of MSD and LSD episodes (all
sites combined) reported by caretakers during the healthcare utilisation and attitudes surveys that met WHO
criteria for dehydration was similar among children who
did and did not seek care at a sentinel hospital or health
centre (appendix).
Figure 2, figure 3, and figure 4 show the attributable
fractions of the pathogens that were significantly
associated with MSD, non-dysentery MSD, and LSD.
During infancy (figure 2), rotavirus was the most common
pathogen associated with non-dysentery MSD at every
site, with overall MSD at all sites except Bangladesh
(where Shigella was also an important cause of MSD), and
with LSD at all sites except India. It predominated as a
cause of MSD and LSD at all sites at age 12–23 months
(figure 3), and at three sites each for MSD and LSD in
the oldest stratum (figure 4). Cryptosporidium spp ranked
second as a cause of MSD among infants at four sites
(The Gambia, Mali, Mozambique, and Pakistan); among
toddlers it ranked first or second in two sites (The Gambia
[ for both MSD and non-dysentery MSD] and Mozambique
[ for non-dysentery MSD]) and was significantly associated
with LSD among infants at four sites (The Gambia,
Mozambique, India, and Pakistan), toddlers at five sites
www.thelancet.com/lancetgh Vol 7 May 2019
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(The Gambia, Mali, Mozambique, Pakistan, and India),
and older children at two sites (The Gambia and Pakistan).
The attributable fraction of Shigella spp increased with
age and was significantly associated with MSD or LSD,
or both, at two sites during infancy (Bangladesh and
Pakistan) and five sites (all sites except Mali) in each of
the older strata. Adenovirus 40 and 41 was associated
with diarrhoea at three sites (India, Bangladesh, and
Mozambique) and norovirus GII at two sites (India and
Bangladesh). H pylori was significantly associated with
diarrhoea at four sites; in India the association was seen in
all age groups, while it was observed in a single age group
in the other three sites (Pakistan, Bangladesh, and Mali).
Differences in pathogen frequency according to the se
verity of watery diarrhoea were evaluated by comparing

non-dysentery MSD versus LSD. Significant differences
were observed only in the two youngest age groups
(figure 2; figure 3). Two pathogens were significantly
more common in non-dysentery MSD compared to LSD:
rotavirus at four sites (India, Bangladesh, Mozambique,
and Pakistan) in the first year of life and at one site in the
12–23 month age group (India), and Cryptosporidium spp
at two sites in the first year of life (Pakistan and
Mozambique) and at one site in the second year of life
(The Gambia). Some pathogens, such as Vibrio cholerae
O1, Aeromonas spp, astrovirus, Campylobacter jejuni,
toxigenic C difficile, and norovirus GII, were significantly
associated with diarrhoea only in Asia. As a result, the
diversity of pathogens appeared greater at the Asian
sites compared with the African sites.
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Figure 5: Attributable incidence of pathogen-specific LSD per 100 child-years of observation, by age stratum, all sites combined
Bars show the incidence values and error bars show the 95% CIs. B fragilis=Bacteroides fragilis. C difficile=Clostridium difficile. E coli=Escherichia coli. ET=enterotoxigenic.
H pylori=Helicobacter pylori. LSD=less-severe diarrhoea. ST=heat-stable-toxin producing. tEP=typical enteropathogenic.
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The overall incidence of LSD among infants from
the DSS population (105·0 episodes per 100 child-years,
95% CI 53·4–156·6) was 3·8 times higher than that of
MSD (27·7 episodes per 100 child-years, 13·2–42·3),
and 4·8 times higher than that of non-dysentery MSD
(21·7 episodes per 100 child-years, 10·0–33·5; table 1).
When the pathogen-specific attributable incidence was
examined across the six sites, the incidence of rotavirus
was highest in relation to the other pathogens for
LSD (22·3 episodes per 100 child-years, 9·4–35·2) and
non-dysenteric MSD (5·4 episodes per 100 child-years,
2·6–8·2) during infancy, and continued to prevail among
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Figure 6: Attributable incidence of pathogen-specific moderate-to-severe diarrhoea (MSD) and
non-dysentery MSD, per 100 child-years of observation, by age stratum, all sites combined
Bars show the incidence values and error bars show the 95% CIs. B fragilis=Bacteroides fragilis. C jejuni=Campylobacter
jejuni. C difficile=Clostridium difficile. EA=enteroaggregative. E coli=Escherichia coli. E histolytica=Entamoeba histolytica.
ET=enterotoxigenic. H pylori=Helicobacter pylori. ST=heat-stable-toxin producing. V cholerae=Vibrio cholerae.
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toddlers at a lower level (figure 5; figure 6). Cryptosporidium
spp contributed the second highest incidence of nondysenteric MSD among infants (2·1 episodes per
100 child-years, 0·8–3·4) and toddlers (0·9 episodes per
100 child-years, 0·1–1·6), while ranking third among
infants and fourth among toddlers as a cause of LSD.
Shigella spp had the third highest incidence for MSD
among infants (1·3 episodes per 100 child-years, 0·3–2·3),
the second among toddlers (2·4 episodes per 100 childyears, 0·6–4·1), and the first among older children
(0·7 episodes per 100 child-years, 0·1–1·3); it ranked
lower as a cause of non-dysenteric MSD and LSD. The
incidence of MSD and non-dysenteric MSD caused by
enterotoxigenic E coli producing heat-stable toxin was less
than 0·2 per 100 child-years in all groups except infants
with non-dysenteric MSD (0·7 episodes per 100 childyears, 0·0–1·4); by contrast, the incidence of LSD caused
by enterotoxigenic E coli producing heat-stable toxin
was 4·2 per 100 child-years (1·0–7·4) among infants,
5·2 per 100 child-years (1·6–8·7) among toddlers, and
1·1 per 100 child-years (0·2–2·0) among young children,
ranking second to rotavirus in the infant and toddler
groups and ranking first among the young-children
group. One notable finding is the appearance of H pylori
in the top five ranking agents in nearly all age groups.
At enrolment, the weighted mean HAZ of both patients
and controls was well below the WHO reference value;
however, patients with both LSD (table 2) and MSD
(table 3) had similar HAZs to their matched controls (all
sites combined within age groups), with the exception of
the infant stratum in the MSD analysis (table 3). At the
follow-up visit, patients in the two highest age strata had
significantly more linear growth faltering than controls
after LSD and after MSD (table 2; table 3).
Children with MSD had significantly lower enrolment
mean HAZs than those with LSD in seven of the
18 site-specific age strata (ie, three age strata in six sites for
a total of 18 strata; table 4). However, when all sites were
combined in age stratum-specific analyses, significant
differences were no longer apparent (table 4). Children
with MSD had significantly more growth faltering over
the approximately 60-day follow-up period than children
with LSD in four of the 18 strata. When all sites were
combined, a significant difference was seen in the infant
stratum (table 4).
We examined patient management according to clinical
syndrome. While at the sentinel hospital or health centre,
oral rehydration salts were given to 471 (19·9%) of
2345 children with MSD and 74 (2·3%) of 3174 children
with LSD; by contrast, most children (5133 [92·6%] of
5542) received a prescription for oral rehydration salts to
be administered at home. A prescription for zinc was
given to 2601 (46·9%) of 5542 children. At the sentinelhospital or health-centre visit, antibiotics were admin
istered to 93 (12·7%) of 730 children with dysentery, to
281 (17·2%) of 1638 children with non-dysentery MSD,
and to 38 (1·2%) of 3174 children with LSD; 557 (76·3%)
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0–11 months
Weighted mean (95% CI)

12–23 months
p value

Weighted mean (95% CI)

24–59 months
p value

Weighted mean (95% CI)

p value

Basse, The Gambia
Number of participants

199 patients; 228 controls

··

183 patients; 236 controls

··

120 patients; 212 controls

··

Patients

–0·56 (–0·74 to –0·38)

0·23

–1·21 (–1·39 to –1·03)

0·73

–1·43 (–1·63 to –1·23)

0·69

Controls

–0·44 (–0·62 to –0·27)

··

–1·19 (–1·35 to –1·04)

··

–1·45 (–1·60 to –1·29)

··

Patients

–0·27 (–0·35 to –0·20)

0·67

–0·23 (–0·28 to –0·17)

0·14

–0·10 (–0·15 to –0·05)

0·10

Controls

–0·23 (–0·31 to –0·14)

··

–0·14 (–0·19 to –0·09)

··

0·01 (–0·03 to 0·05)

··

··

201 patients; 202 controls

··

Enrolment HAZ

ΔHAZ

Bamako, Mali
Number of participants

204 patients; 204 controls

208 patients; 208 controls

··

Enrolment HAZ
Patients

–0·57 (–0·72 to –0·41)

0·81

–0·88 (–1·04 to –0·72)

0·10

–1·07 (–1·22 to –0·93)

0·17

Controls

–0·63 (–0·81 to –0·46)

··

–1·06 (–1·21 to –0·91)

··

–0·92 (–1·07 to –0·77)

··

Patients

–0·37 (–0·44 to –0·31)

0·31

–0·08 (–0·11 to –0·04)

0·39

0·06 (0·03 to 0·09)

0·18

Controls

–0·32 (–0·39 to –0·25)

··

–0·04 (–0·09 to 0·01)

··

0·07 (0·05 to 0·10)

··

136 patients; 136 controls

··

Patients

–0·83 (–1·04 to –0·63)

0·61

–1·30 (–1·51 to –1·10)

Controls

–0·91 (–1·10 to –0·73)

··

–1·57 (–1·75 to –1·39)

··

Patients

–0·03 (–0·15 to 0·08)

0·64

–0·04 (–0·11 to 0·04)

0·65

–0·03 (–0·09 to 0·02)

Controls

–0·07 (–0·18 to 0·04)

··

–0·03 (–0·11 to 0·05)

··

0·05 (0·00 to 0·11)

ΔHAZ

Manhiça, Mozambique
Number of participants

148 patients; 148 controls

··

81 patients; 81 controls

··

–1·52 (–1·80 to –1·24)

0·56

–1·63 (–1·86 to –1·40)

··

Enrolment HAZ
0·033

ΔHAZ
0·020
··

Kolkata, India
Number of participants

194 patients; 194 controls

··

171 patients; 183 controls

··

175 patients; 181 controls

··

Patients

–1·12 (–1·28 to –0·97)

0·95

–1·47 (–1·64 to –1·30)

0·28

–1·74 (–1·91 to 1·56)

0·39

Controls

–1·13 (–1·28 to –0·98)

··

–1·29 (–1·44 to –1·15)

··

–1·64 (–1·80 to –1·47)

··

Patients

–0·10 (–0·15 to –0·06)

0·12

–0·07 (–0·09 to –0·04)

0·42

–0·03 (–0·04 to –0·02)

0·72

Controls

–0·05 (–0·09 to –0·01)

··

–0·02 (–0·06 to 0·01)

··

–0·03 (–0·04 to –0·01)

··

176 patients; 344 controls

··

146 patients; 287 controls

··

82 patients; 243 controls

··

Patients

–1·06 (–1·26 to –0·85)

0·60

–1·05 (–1·23 to –0·88)

0·13

–0·98 (–1·20 to –0·76)

Controls

–1·05 (–1·19 to –0·92)

··

–1·32 (–1·44 to –1·19)

··

–1·43 (–1·56 to –1·30)

··

Patients

–0·21 (–0·29 to –0·14)

0·67

–0·16 (–0·22 to –0·10)

0·24

–0·09 (–0·13 to –0·05)

0·28

Controls

–0·23 (–0·27 to –0·18)

··

–0·11 (–0·15 to –0·08)

··

–0·05 (–0·07 to –0·02)

··

··

89 patients; 217 controls

..

Enrolment HAZ

ΔHAZ

Mirzapur, Bangladesh
Number of participants
Enrolment HAZ
0·0058

ΔHAZ

Karachi (Bin Qasim Town), Pakistan
Number of participants

161 patients; 162 controls

··

133 patients; 219 controls

Enrolment HAZ
Patients

–1·31 (–1·50 to –1·12)

0·71

–2·04 (–2·27 to –1·81)

0·18

–2·34 (–2·67 to –2·02)

0·73

Controls

–1·26 (–1·49 to –1·03)

··

–1·97 (–2·13 to –1·81)

··

–2·28 (–2·45 to –2·11)

··

Patients

–0·09 (–0·19 to 0·01)

0·18

–0·28 (–0·36 to –0·20)

Controls

–0·16 (–0·26 to –0·06)

··

–0·16 (–0·21 to –0·10)

ΔHAZ
0·0012
··

–0·04 (–0·11 to 0·02)
0·06 (0·02 to 0·09)

0·0043
··

(Table 2 continues on next page)
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0–11 months
Weighted mean (95% CI)

12–23 months
p value

Weighted mean (95% CI)

24–59 months
p value

Weighted mean (95% CI)

p value

(Continued from previous page)
All sites combined
Number of participants

1070 patients; 1268 controls

··

982 patients; 1275 controls

··

755 patients; 1142 controls

··

Patients

–0·98 (–1·07 to –0·88)

0·70

–1·47 (–1·58 to –1·37)

0·96

–1·79 (–1·94 to –1·64)

0·87

Controls

–0·95 (–1·04 to –0·85)

··

–1·55 (–1·63 to –1·47)

··

–1·88 (–1·98 to –1·77)

··

Patients

–0·16 (–0·21 to –0·12)

0·23

–0·18 (–0·21 to –0·15)

Controls

–0·18 (–0·22 to –0·14)

··

–0·11 (–0·14 to –0·09)

Enrolment HAZ

ΔHAZ
0·0040
··

–0·04 (–0·07 to –0·01)

<0·0001

0·03 (0·01 to 0·55)

··

Enrolment HAZ in patients versus controls was compared by weighted paired t test; ΔHAZ in patients versus controls was compared by weighted linear regression, adjusting
for enrolment HAZ and duration to follow–up. HAZ=length–for–age or height–for–age Z score. ΔHAZ=change in HAZ (ie, HAZ at follow–up visit [50–90 days after enrolment]
minus HAZ at enrolment).

Table 2: Comparison of enrolment HAZ and ΔHAZ between patients with less severe diarrhoea and their matched controls, by site

0–11 months
Weighted mean (95% CI)

12–23 months
p value

Weighted mean (95% CI)

24–59 months
p value

Weighted mean (95% CI)

p value

Basse, The Gambia
Number of participants

103 patients; 155 controls

··

131 patients; 199 controls

··

62 patients; 135 controls

··

Patients

–0·90 (–1·12 to –0·68)

0·30

–1·53 (–1·73 to –1·33)

0·26

–1·82 (–2·08 to –1·55)

0·30

Controls

–0·70 (–0·90 to –0·50)

··

–1·35 (–1·54 to –1·15)

··

–1·53 (–1·69 to –1·36)

··

Patients

–0·37 (–0·47 to –0·26)

0·93

–0·30 (–0·37 to –0·24)

–0·03 (–0·10 to 0·05)

0·57

Controls

–0·20 (–0·29 to –0·12)

··

–0·09 (–0·15 to –0·03)

0·08 (0·04 to 0·13)

··

Enrolment HAZ

ΔHAZ
0·091
··

Bamako, Mali
Number of participants

206 patients; 206 controls

··

206 patients; 206 controls

··

191 patients; 191 controls

··

Patients

–0·50 (–0·64 to –0·36)

0·31

Controls

–0·57 (–0·76 to –0·38)

··

–1·15 (–1·29 to –1·00)

0·67

–1·18 (–1·35 to –1·00)

0·41

–1·04 (–1·18 to –0·90)

··

–1·06 (–1·22 to –0·89)

··

Patients

–0·40 (–0·45 to –0·34)

0·17

–0·09 (–0·13 to –0·05)

Controls

–0·34 (–0·41 to –0·27)

··

–0·04 (–0·08 to 0·00)

0·14

0·06 (0·03 to 0·09)

0·18

··

0·11 (0·08 to 0·14)

··

55 patients; 145 controls

··

37 patients;101 controls

··

Enrolment HAZ

ΔHAZ

Manhiça, Mozambique
Number of participants

22 patients; 60 controls

··

Enrolment HAZ
Patients

–1·39 (–1·77 to –1·01)

–1·66 (–2·18 to –1·14)

0·62

–1·07 (–1·59 to –0·55)

Controls

–0·74 (–0·91 to –0·57)

0·050
··

–1·52 (–1·74 to –1·30)

··

–1·45 (–2·02 to –0·88)

0·033
··

Patients

–0·01 (–0·16 to –0·15)

0·62

–0·27 (–0·39 to –0·14)

0·10 (–0·04 to 0·23)

0·72

Controls

–0·08 (–0·17 to –0·02)

··

–0·01 (–0·09 to 0·07)

0·08 (0·01 to 0·15)

··

ΔHAZ
0·038
··

Kolkata, India
Number of participants

189 patients; 190 controls

··

147 patients; 160 controls

··

163 patients; 186 controls

··

Enrolment HAZ
Patients

–1·12 (1·26 to –0·98)

0·70

–1·30 (–1·48 to –1·12)

0·66

–1·90 (–2·09 to –1·71)

0·29

Controls

–1·14 (–1·30 to –0·98)

··

–1·44 (–1·65 to –1·24)

··

–1·61 (–1·76 to –1·45)

··

Patients

–0·07 (–0·11 to –0·02)

0·41

–0·06 (–0·09 to –0·04)

0·47

–0·01 (–0·02 to 0·01)

0·87

Controls

–0·02 (–0·06 to 0·02)

··

–0·04 (–0·07 to –0·01)

··

–0·01 (–0·02 to 0·00)

··

ΔHAZ

(Table 3 continues on next page)
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0–11 months
Weighted mean (95% CI)

12–23 months
p value

Weighted mean (95% CI)

24–59 months
p value

Weighted mean (95% CI)

p value

(Continued from previous page)
Mirzapur, Bangladesh
Number of participants

121 patients; 241 controls

··

102 patients; 201 controls

··

93 patients; 270 controls

··

Enrolment HAZ
Patients

–1·05 (–1·24 to –0·85)

–1·30 (–1·53 to –1·06)

0·95

–1·29 (–1·51 to –1·07)

0·52

Controls

–1·00 (–1·15 to –0·86)

0·071
··

–1·31 (–1·47 to –1·15)

··

–1·42 (–1·55 to –1·29)

··

Patients

–0·20 (–0·30 to –0·10)

0·36

–0·11 (–0·16 to –0·06)

0·51

–0·09 (–0·13 to –0·05)

Controls

–0·25 (–0·31 to –0·20)

··

–0·07 (–0·12 to –0·03)

··

–0·05 (–0·08 to –0·03)

··

··

89 patients; 163 controls

··

62 patients; 159 controls

··

ΔHAZ
0·016

Karachi (Bin Qasim Town), Pakistan
Number of participants

108 patients; 108 controls

Enrolment HAZ
Patients

–1·68 (–1·92 to –1·43)

Controls

–1·24 (–1·48 to –1·00)

0·065
··

–2·08 (–2·33 to –1·83)

0·84

–2·55 (–2·89 to –2·22)

0·42

–2·03 (–2·23 to –1·83)

··

–2·32 (–2·52 to –2·13)

··

Patients

–0·17 (–0·29 to –0·05)

Controls

–0·22 (–0·35 to –0·10)

0·88

–0·20 (–0·31 to –0·10)

0·26

–0·09 (–0·17 to –0·02)

··

–0·12 (–0·20 to –0·04)

··

0·01 (–0·04 to 0·07)

ΔHAZ
0·071
··

All sites combined
Number of participants

782 patients; 1045 controls

··

712 patients; 1030 controls

··

593 patients; 1001 controls

··

Enrolment HAZ
Patients

–1·07 (–1·16 to –0·98)

Controls

–0·89 (–0·97 to –0·82)

0·030
··

–1·50 (–1·59 to –1·40)

0·31

–1·69 (–1·81 to –1·57)

0·35

–1·48 (–1·57 to –1·40)

··

–1·65 (–1·73 to –1·56)

··

Patients

–0·23 (–0·27 to –0·19)

0·41

–0·17 (–0·21 to –0·14)

Controls

–0·19 (–0·23 to –0·16)

··

–0·07 (–0·10 to –0·05)

ΔHAZ
0·0002
··

–0·02 (–0·04 to 0·00)
0·02 (0·00 to 0·04)

0·0061
··

Enrolment HAZ in patients versus controls was compared by weighted paired t test; ΔHAZ in patients versus controls was compared by weighted linear regression, adjusting
for enrolment HAZ and duration to follow–up. HAZ=length–for–age or height–for–age Z score. ΔHAZ=change in HAZ (ie, HAZ at follow–up visit [50–90 days after enrolment]
minus HAZ at enrolment).

Table 3: Comparison of enrolment HAZ and ΔHAZ between patients with moderate–to–severe diarrhoea and their matched controls, by site

of 730 children with dysentery, 573 (34·9%) of
1638 children with non-dysentery MSD, and 1788 (56·3%)
of 3174 children with LSD received a prescription for
antibiotics for administration at home after discharge
from the sentinel hospital or health centre.

Discussion
Results from this study corroborate several important
observations from GEMS about the aetiology and adverse
clinical consequences of MSD among children under
5 years of age living in low-income communities in
sub-Saharan Africa and south Asia, and extend those
findings to a much broader population of children.2
GEMS demonstrated that four pathogens (rotavirus,
Cryptosporidium spp, enterotoxigenic E coli producing heatstable toxin, and Shigella spp) were responsible for the
majority of attributable MSD cases. Inclusion of LSD in
the current study revealed a far greater burden contributed
by these pathogens. By estimating the attributable fraction
and the attributable incidence of pathogen-specific MSD
and LSD, our data not only show the proportion of episodes
that might be prevented by using an effective intervention,
but also characterise the public health impact that such an
www.thelancet.com/lancetgh Vol 7 May 2019

intervention might have.17 Even if a vaccine were less
effective against LSD than MSD, as has been the case for
rotavirus vaccines,18 the vaccine would be expected to
prevent many more episodes of LSD than of MSD.
Children with MSD in general were not more stunted
at baseline than those with LSD. Thus, we cannot attribute
the increased severity of their diarrhoeal illness to their
pre-existing linear growth faltering. Moreover, despite
evident differences in illness severity, children with both
syndromes demonstrated linear growth faltering relative
to their matched healthy controls during the 2–3 months
after their illness. These findings illustrate the importance
of preventing both LSD and MSD from the perspective of
mitigating the adverse nutritional consequences of
young-child diarrhoeal illness.
This study also provided a broad view of the patient
management of diarrhoeal disease at health centres
in Africa and Asia. The purported trends toward
diminishing prioritisation and funding of diarrhoea
control programmes in low-income and middle-income
countries19 are perhaps reflected in the suboptimal
centre-based administration of oral rehydration salts at
our sites. Few children actually received these fluids
e580
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during their visit and instead oral rehydration salts were
prescribed at the sentinel hospital or health centre but
left to the child’s caretakers to procure and administer at
home. Without substantial investment of resources to
support intense promotion of oral rehydration salt use at
0–11 months
Weighted mean (95% CI)

the community level, it is unlikely that the full public
health impact of oral rehydration salts will be realised.19
Moreover, it is uncertain whether oral rehydration salts
and zinc alone will be sufficient to prevent growth
faltering and reduce diarrhoea-related fatalities that we
12–23 months

p value

Weighted mean (95% CI)

24–59 months
p value

Weighted mean (95% CI) p value

Basse, The Gambia
Number of participants

199 LSD patients; 103 MSD
patients

··

183 LSD patients; 131 MSD
patients

··

120 LSD patients;
62 MSD patients

··

Enrolment HAZ
LSD patients

–0·56 (–0·74 to –0·38)

MSD patients

–0·90 (–1·12 to –0·68)

0·020
··

–1·21 (–1·39 to –1·03)
–1·53 (–1·73 to –1·33)

0·020
··

–1·43 (–1·63 to –1·23)

0·023

–1·82 (–2·08 to –1·55)

··

–0·10 (–0·15 to –0·05)

0·22

–0·03 (–0·10 to 0·05)

··

ΔHAZ
LSD patients

–0·27 (–0·35 to –0·20)

MSD patients

–0·37 (–0·47 to –0·26)

0·038
··

204 LSD patients; 206 MSD
patients

··

–0·23 (–0·28 to –0·17)
–0·30 (–0·37 to –0·24)

0·013
··

Bamako, Mali
Number of participants

201 LSD patients;
206 MSD patients

··

208 LSD patients;
191 MSD patients

··

Enrolment HAZ
LSD patients

–0·57 (–0·72 to –0·41)

0·52

–0·88 (–1·04 to –0·72)

MSD patients

–0·50 (–0·64 to –0·36)

··

–1·15 (–1·29 to –1·00)

0·015
··

–1·07 (–1·22 to –0·93)

0·38

–1·18 (–1·35 to –1·00)

··

LSD patients

–0·37 (–0·44 to –0·31)

0·85

–0·08 (–0·11 to –0·04)

MSD patients

–0·40 (–0·45 to –0·34)

··

–0·09 (–0·13 to –0·05)

0·16

0·06 (0·03 to 0·09)

0·80

··

0·06 (0·03 to 0·09)

··

136 LSD patients; 55 MSD
patients

··

148 LSD patients; 37 MSD
patients

··

81 LSD patients; 22 MSD
patients

··

–1·30 (–1·51 to –1·10)

0·19

–1·52 (–1·80 to –1·24)

0·12

–1·66 (–2·18 to –1·14)

··

–1·07 (–1·59 to –0·55)

··

ΔHAZ

Manhiça, Mozambique
Number of participants
Enrolment HAZ
LSD patients

–0·83 (–1·04 to –0·63)

MSD patients

–1·39 (–1·77 to –1·01)

0·010
··

LSD patients

–0·03 (–0·15 to –0·08)

0·70

–0·04 (–0·11 to –0·04)

MSD patients

–0·01 (–0·16 to –0·15)

··

–0·27 (–0·39 to –0·14)

ΔHAZ
0·0020
··

–0·03 (–0·09 to 0·02)
0·10 (–0·04 to 0·23)

0·033
··

Kolkata, India
Number of participants

194 LSD patients; 189 MSD
patients

··

171 LSD patients; 147 MSD
patients

··

175 LSD patients;
163 MSD patients

··

LSD patients

–1·12 (–1·28 to –0·97)

0·94

–1·47 (–1·64 to –1·30)

0·18

–1·74 (–1·91 to 1·56)

0·21

MSD patients

–1·12 (1·26 to –0·98)

··

–1·30 (–1·48 to –1·12)

··

–1·90 (–2·09 to –1·71)

··

LSD patients

–0·10 (–0·15 to –0·06)

0·27

–0·07 (–0·09 to –0·04)

0·80

–0·03 (–0·04 to –0·02)

0·20

MSD patients

–0·07 (–0·11 to –0·02)

··

–0·06 (–0·09 to –0·04)

··

–0·01 (–0·02 to 0·01)

··

176 LSD patients; 121 MSD
patients

··

LSD patients

–1·06 (–1·26 to –0·85)

0·94

MSD patients

–1·05 (–1·24 to –0·85)

··

LSD patients

–0·21 (–0·29 to –0·14)

MSD patients

–0·20 (–0·30 to –0·10)

Enrolment HAZ

ΔHAZ

Mirzapur, Bangladesh
Number of participants

146 LSD patients;
102 MSD patients

··

82 LSD patients; 93 MSD
patients

··

–1·05 (–1·23 to –0·88)

0·10

–0·98 (–1·20 to –0·76)

–1·30 (–1·53 to –1·06)

··

–1·29 (–1·51 to –1·07)

··

0·95

–0·16 (–0·22 to –0·10)

0·48

–0·09 (–0·13 to –0·05)

0·69

··

–0·11 (–0·16 to –0·06)

··

–0·09 (–0·13 to –0·05)

··

Enrolment HAZ
0·045

ΔHAZ

(Table 4 continues on next page)
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0–11 months
Weighted mean (95% CI)

12–23 months
p value

Weighted mean (95% CI)

24–59 months
p value

Weighted mean (95% CI) p value

(Continued from previous page)
Karachi (Bin Qasim Town), Pakistan
Number of participants

161 LSD patients; 108 MSD
patients

··

133 LSD patients; 89 MSD
patients

··

89 LSD patients; 62 MSD
patients

··

Enrolment HAZ
LSD patients

–1·31 (–1·50 to –1·12)

–2·04 (–2·27 to –1·81)

0·82

–2·34 (–2·67 to –2·02)

0·38

MSD patients

–1·68 (–1·92 to –1·43)

0·021
··

–2·08 (–2·33 to –1·83)

··

–2·55 (–2·89 to –2·22)

··

LSD patients

–0·09 (–0·19 to 0·01)

0·25

–0·28 (–0·36 to –0·20)

0·16

–0·04 (–0·11 to 0·02)

MSD patients

–0·17 (–0·29 to –0·05)

··

–0·20 (–0·31 to –0·10)

··

–0·09 (–0·17 to –0·02)

1070 LSD patients; 782 MSD
patients

··

LSD patients

–0·98 (–1·07 to –0·88)

0·17

–1·47 (–1·58 to –1·37)

0·78

–1·79 (–1·94 to –1·64)

0·30

MSD patients

–1·07 (–1·16 to –0·98)

··

–1·50 (–1·59 to –1·40)

··

–1·69 (–1·81 to –1·57)

··

–0·18 (–0·21 to –0·15)

0·77

–0·04 (–0·07 to –0·009)

0·19

–0·17 (–0·21 to –0·14)

··

–0·02 (–0·04 to 0·003)

··

ΔHAZ
0·090
··

All sites combined
Number of participants

982 LSD patients;
712 MSD patients

··

755 LSD patients;
593 MSD patients

··

Enrolment HAZ

ΔHAZ
LSD patients

–0·16 (–0·21 to –0·12)

MSD patients

–0·23 (–0·27 to –0·19)

0·018
··

Enrolment HAZ in patients with LSD versus patients with MSD was compared by weighted linear regression. ΔHAZ was compared by weighted linear regression, adjusting for
enrolment HAZ and duration to follow–up. HAZ=length–for–age or height–for–age Z score. ΔHAZ=change in HAZ (ie, HAZ at follow–up visit [50–90 days after enrolment]
minus HAZ at enrolment). LSD=less severe diarrhoea. MSD=moderate–to–severe diarrhoea.

Table 4: Comparison of enrolment HAZ and ΔHAZ between patients with LSD and patients with MSD, by site.

have found to be associated with several important
causes of MSD and LSD in low-resource settings, such
as Cryptosporidium spp, enterotoxigenic E coli producing
heat-stable toxin, and Shigella spp,2 which induce
intestinal pathology in addition to fluid loss. The
development and evaluation of strategies for prevention
and treatment of these three pathogens for use in lowresource settings and the impact of these interventions
on the acute and longer-term consequences of diarrhoea
should be research priorities.
Our case-control study identified an association
between H pylori and diarrhoeal disease (both MSD and
LSD) at multiple sites, affecting all age groups, and at all
three Asian sites and at the Mali site. Our findings are
supported by a longitudinal study of Peruvian children
aged 6 months to 12 years that observed an increased
incidence of diarrhoea during the first 2 months after
acquisition of acute H pylori infection.20 Although both
studies raise the prospect that H pylori is a diarrhoeal
pathogen, one cannot exclude the possibility that it is a
modifier that increases susceptibility to certain other
enteropathogens, or a co-traveller that shares risk factors
with other enteric infections, such as contaminated
drinking water, household crowding, and inadequate
hygiene.21 Studies that support the modifier theory,
perhaps mediated by the propensity of persistent
H pylori infection to cause hypochlorhydria, have found
that children and adults with H pylori infection had an
increased risk of typhoid fever in India22 and an increased
www.thelancet.com/lancetgh Vol 7 May 2019

severity (but not risk) of cholera in Bangladesh.23
Evidence shedding doubt on the diarrhoeagenicity of
H pylori includes findings that seronegative US adults
who were challenged with H pylori did not report
diarrhoeal symptoms.24–26 Additionally, three prospective
studies among children younger than 5 years in de
veloping countries did not find an overall increase in the
incidence of diarrhoea in those with H pylori infection;
however, methodological issues such as enrolment of
children with pre-existing infection confound the
interpretation of these findings.27–29
In many respects, the findings of GEMS-1A (and its
parent study GEMS2) are complemented by the
Malnutrition and Enteric Disease (MAL-ED) study,30 a
contemporaneous multicentre, longitudinal, communitybased cohort study of enteric infections among infants
aged 0–23 months in eight low-income and middleincome countries. Both studies measured the proportion
of diarrhoeal disease that was attributable to a broad
array of pathogens, adjusting for asymptomatic detection
of pathogens in controls, and both evaluated the impact
of illness on growth and mortality. By design, children
enrolled in GEMS and GEMS-1A were more severely
ill, inhabited more impoverished environments, and
spanned a broader age range, as detailed in a comparison
published elsewhere.31 A minority (25·0%) of MAL-ED
cases met the definition of LSD (ie, sought care at a
health centre but were not considered MSD) and only
10·2% met criteria for MSD.32 Accordingly, compared
e582
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with mortality among children in MAL-ED (0·05%)32
mortality in GEMS-1A was ten times higher among
children with LSD and 20 times higher among children
with MSD (unpublished). Moreover, the small reductions
in HAZ (<-0·025) at 3 months associated with diarrhoea
in MAL-ED33 were substantially lower than those seen
among similarly aged children after LSD and MSD in
GEMS-1A. These data illustrate the greater morbidity
and mortality associated with the medically attended,
more clinically severe diarrhoeal diseases included in
GEMS-1A than with the milder episodes identified in the
community during MAL-ED, and could help to explain
the absence of association between diarrhoeal disease
and growth faltering observed in MAL-ED.33 The relative
contribution of various pathogens to the attributable
disease burden could also contribute to the degree of
growth faltering observed. Keeping in mind that crossstudy comparisons must be interpreted with caution, it
appears that a broader spectrum of pathogens (assessed
with conventional assays because quantitative PCR was
not used in GEMS-1A) is associated with the less severe
diarrhoeal episodes in GEMS-1A and MAL-ED,30 whereas
fewer, and perhaps more pathogenic organisms (eg,
rotavirus, Cyptosporidium spp, and Shigella spp), were
associated with a greater proportion of the more severe
MSD episodes.
Several limitations must be considered when inter
preting the results of this study. For one, enrolment was
undertaken for only one calendar year, thus limiting
statistical power for comparisons. The method for
calculating incidence by using the proportion of children
with MSD or LSD taken to one of the site’s sentinel
hospitals or health centres to derive overall and pathogenspecific population-based incidence values assumes that
pathogen distribution is similar in participants who seek
and do not seek care at a sentinel hospital or health
centre. This is a limitation particularly when applied to
LSD. In the absence of unique clinical parameters to
define LSD, incident cases included all episodes of
diarrhoea occurring in the community that were not
MSD, which encompass a range of severity. If LSD
episodes seen at the sentinel hospital or health centre
were more severe than those of children not seeking
care at the sentinel hospital or health centre, then the
pathogen-specific incidence values that were calculated
on the basis of the pathogens identified among LSD
cases at the sentinel hospital or health centre might be
over-represented. It is thus reassuring that the proportion
of children with LSD in the community who met WHO
criteria for dehydration was similar to that seen among
patients with LSD who sought care at the sentinel hospital
or health centre. Moreover, our estimates of the overall
incidence of acute, new-onset diarrhoeal disease (ie, MSD
plus LSD) were considerably lower than reported
elsewhere, so our measurements might actually represent
underestimates.34 Finally, parents participating in the
health-care utilisation and attitudes surveys probably
e583

under-reported milder diarrhoeal episodes occurring
during the previous 7 days.7,35
In summary, our results show that the same
four pathogens—ie, rotavirus, Cryptosporidum spp,
Shigella spp, and enterotoxigenic E coli producing heatstable toxin—are responsible for most episodes of MSD
and LSD. Our findings markedly expand the numbers
of children adversely affected nutritionally by the
consequences of diarrhoeal diseases but do not alter
the focus of preventive efforts. The development and
evaluation of strategies for prevention and treatment of
Cryptosporidium spp, Shigella spp, and enterotoxigenic
E coli producing heat-stable toxin for use in low-resource
settings and the impact of these interventions on the
acute and long-term consequences of diarrhoea should
be priorities for future investigations.
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